Hi Tony,
In reading through the Chairman's Report I completely overlooked the significance of the recent deal with Cubist Pharmaceuticals. Firstly, the top of Page 5 highlights Phylogica's strategy to monetise non-core assets including antimicrobial peptides which is "available for out-licensing". Directly below is a report on the Cubist deal. Cubist are evaluating several of our antimicrobial peptides.
Initially, there was some disappointment by shareholders that Cubist didn't enter into a collaborative arrangement with Phylogica similar to the Janssen deal. It would appear, however, that Cubist has simply gone to the head of the queue and are evaluating our in-house antimicrobial program with the intention of licensing promising leads. Our first licensing deal may be closer than what we thought.
Wayne.
- Forums
- ASX - By Stock
- janssen
PYC
pyc therapeutics limited
Add to My Watchlist
3.03%
!
$1.28

Hi Tony,In reading through the Chairman's Report I completely...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.28 |
Change
-0.040(3.03%) |
Mkt cap ! $746.5M |
Open | High | Low | Value | Volume |
$1.32 | $1.35 | $1.28 | $764.7K | 579.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | $1.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.30 | 40248 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | 1.275 |
1 | 13987 | 1.265 |
2 | 16060 | 1.260 |
1 | 12000 | 1.255 |
2 | 2800 | 1.250 |
Price($) | Vol. | No. |
---|---|---|
1.300 | 40248 | 3 |
1.330 | 5000 | 1 |
1.345 | 53113 | 2 |
1.350 | 22000 | 2 |
1.360 | 5958 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online